British Journal of Cancer - Abstract of article: Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

Advertisement

British Journal of Cancer homepage

British Journal of Cancer (2006) 94, 1550–1552. doi:10.1038/sj.bjc.6603114 www.bjcancer.com
Published online 25 April 2006

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer

G L Banna¹, S M L Aversa¹, G Crivellari¹, C Ghiotto¹, V Chiarion-Sileni¹ and S Monfardini¹

¹Division of Medical Oncology, Istituto Oncologico Veneto, Via Gattamelata 64, Padova 35100, Italy

Correspondence: Dr GL Banna, E-mail: gbanna@yahoo.com

Top

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated

REVIEWS

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nature Clinical Practice Oncology Review (01 May 2006)

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nature Clinical Practice Oncology Review (01 May 2006)

Trastuzumab: triumphs and tribulations

Oncogene Review

RESEARCH

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

British Journal of Cancer Original Article

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Oncogene Original Article

See all 3 matches for Research

ABSTRACT NAVIGATION - ABSTRACT

Previous | Next

Export citation

nature jobs

Research Scientist
- Children's Hospital of Pittsburgh
- Pittsburgh, PA
Fellowships
- Brighams and Women's Hospital
- Boston, MA

More science jobs

Post a job for free